Companies category powered by

Remedica signs MoU with Saudi AJA Pharma

Remedica has signed a non-binding memorandum of understanding (MoU) with AJA Pharma, a subsidiary of Saudi Chemical Company Holding (SCCH), marking the beginning of a strategic collaboration.

As part of this partnership, Cypriot pharmaceutical company Remedica and AJA Pharma will join forces to develop medicines and transfer technology, combining the strengths of the two companies to drive innovation and enter new markets.

MixCollage-14-Nov-2024-02-50-PM-19

“The Saudi market is not only pivotal in the Middle East, but also increasingly influential on the global stage,” Vijay Zutshi, Chief Commercial & Strategy Officer at Remedica said, adding: “Its rapid growth, strategic geographic position, and ambitious Vision 2030 reform plan make it a key player in shaping future economic trends and driving innovation across the healthcare industry. We are excited about our partnership with AJA Pharma that reinforces our shared mission to deliver innovative and high-quality pharmaceutical solutions and expands our reach to patient needs across key disease areas like Oncology, Cardiovascular, and Diabetes, in both tablets and injectables.”

Read More

Evgenios Evgeniou: €3.2b in foreign investments over 2023, creating 2,500 new jobs
Morningstar DBRS says that Cypriot NPLs remain stable
Finance Minister welcomes Eurostat results, says government policy to continue
Remedica signs MoU with Saudi AJA Pharma
George Hasapakos: We decided to set up in Cyprus to offer our existing European clients a second choice of location for Nearshore Support and Services
New RIF program: Funding opportunities up to €150,000 for Cypriot businesses
Christos Patsalides LLC and Kakkouras and Panayides LLC join forces
UNSG remains committed to informal expanded talks, Dujarric says on Cyprus issue
Successful EU Presidency a high priority, Dep. Minister for European Affairs says
China-Cyprus trade at one billion dollars in 2023, Chinese Ambassador says